Researchers at the NIH and Emory School of Medicine have completed the first minimally invasive coronary artery bypass of the ...
(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) Jan ...
MADRID, Spain—Adding evolocumab (Repatha; Amgen) to statin therapy does not lower the risk of saphenous vein graft (SVG) failure among patients who undergo coronary artery bypass surgery, the ...
For many, the thought of heart bypass surgery comes with the fear of slowing down, giving up adventures, and leading a ...
Madrid, Spain – 1 September 2025: After coronary artery bypass grafting (CABG), evolocumab did not reduce saphenous vein graft disease rates at 2 years compared with placebo, according to ...
Addition of the PCSK9 inhibitor evolocumab to statin therapy after cardiac bypass surgery did not improve 24-month graft patency in the NEWTON-CABG CardioLink-5 trial. Subodh Verma, MD, cardiac ...
Madrid, Spain – 1 September 2025: Compared with dual antiplatelet therapy (DAPT), a de-escalated DAPT strategy resulted in similar graft occlusion rates and reduced clinically relevant bleeding in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results